<DOC>
	<DOCNO>NCT00479765</DOCNO>
	<brief_summary>OncoGel™ new , experimental drug delivery system allow slow continuous release paclitaxel ( approve intravenous anticancer drug ) , gel ( ReGel™ ) long period time . The gel disappear 4 6 week release paclitaxel . The purpose study evaluate safety tolerability OncoGel place tumor resection cavity brain follow surgical removal tumor . Dose escalation conduct gradually increase amount OncoGel place resection cavity small group patient , watch patient closely side effect move next dose level . The study also test whether OncoGel help prevent delay tumor regrowing .</brief_summary>
	<brief_title>A Phase 1 / 2 Dose Escalation Study Locally-Administered OncoGel™ Subjects With Recurrent Glioma</brief_title>
	<detailed_description>This study patient recurrent glioblastoma multiforme . Because recurrence area original resection , local delivery chemotherapeutic agent may prevent delay additional recurrence . Paclitaxel demonstrate activity 9L glioma tumor line , poor central nervous system penetration intravenous administration . OncoGel new formulation paclitaxel bioerodible gel administer directly brain , thereby bypass blood-brain barrier .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>At least 18 less 70 year age Radiological evidence MRI progressive recurrent malignant glioma unilateral , unifocal , supratentorial minimum tumor volume require per dose level assignment Tumor must solid contrast enhance component Gross total resection &gt; 95 % recurrence must plan Must receive prior conventional radiation therapy complete &gt; 4 week Study Day 1 ( ie , day craniotomy OncoGel administration ) Previous cytoreductive surgery biopsy pathologic diagnosis glioblastoma multiforme Diagnosis glioma time debulking surgery recurrence ( frozen section squash preparation ) Life expectancy &gt; 2 month KPS great equal 70 Using appropriate birth control , female childbearing potential ; Able willing participate study signing inform consent document Contrastenhancing tumor cross midline Multifocal noncontiguous tumor result multiple resection cavity Evidence tumor dissemination ( ependymal , leptomeningeal ) Tumors result lobectomy resection leave insufficient residual cavity receive expect OncoGel volume Expected communication ventricle resection cavity repair Involvement primary sensorimotor cortex dominant hemisphere within 1.5 cm optic chiasm , either optic nerve cranial nerve Significantly increase intracranial pressure Received type stereotactic radiosurgery brachytherapy exception stereotactic radiosurgery boost part initial radiation therapy History seizures refractory two anticonvulsant medication coadministered therapeutic level Impaired organ function evidence clinically significant laboratory parameter include limited following : Hepatic Status : Bilirubin &gt; 2.0 mg/dL ; Aspartate transaminase ( AST ) &gt; 2.5 time normal limit ; Alanine aminotransferase ( ALT ) &gt; 2.5 time normal limit . Hematopoietic Status : Absolute neutrophil count ( ANC ) &lt; 1500mm3 ; Platelet count &lt; 100,000/mm3 ; Hemoglobin &lt; 10 g/dL . Hemostatic : Prothrombin Time ( PT ) INR normal range ; Partial Thromboplastin Time ( PTT ) normal range ; Bleeding Time outside normal range ( performed hospital ) . Renal Status : Serum creatinine &gt; 2 mg/dL . Contraindication MRI Receipt chemotherapeutic agent within 28 day Study Day 1 nitrosourea within 6 week Study Day 1 Received intracerebral investigational agent Receipt another investigational drug device within 28 day plan surgery Known history allergy paclitaxel component OncoGel Pregnant lactate Concurrent lifethreatening disease Any medical condition circumstance , opinion Investigator , would make subject unlikely unable successfully complete study , would interfere analysis study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>recurrent</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Phase I</keyword>
	<keyword>Phase II</keyword>
	<keyword>brain</keyword>
	<keyword>cancer</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>intracranial</keyword>
	<keyword>tumor</keyword>
	<keyword>local</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>brain tumor</keyword>
	<keyword>brain cancer</keyword>
	<keyword>glioma</keyword>
	<keyword>OncoGel</keyword>
</DOC>